TG Therapeutics Announces Pharmacokinetic, Pharmacodynamic, Safety, And Tolerability Data From Phase 1 Clinical Trial Evaluating Subcutaneous Formulation Of Ublituximab As Compared To IV BRIUMVI

Loading news article.

TG Therapeutics Announces Pharmacokinetic, Pharmacodynamic, Safety, And Tolerability Data From Phase 1 Clinical Trial Evaluating Subcutaneous Formulation Of Ublituximab As Compared To IV BRIUMVI | WAPE

TG Therapeutics Announces Pharmacokinetic, Pharmacodynamic, Safety, And Tolerability Data From Phase 1 Clinical Trial Evaluating Subcutaneous Formulation Of Ublituximab As Compared To IV BRIUMVI

Article summary

Related companies

Comments —